Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts
Scientific News
NIH-supported Clinical Trials to Evaluate Long-acting, Injectable Antiretroviral Drugs
Both trials are expected to be completed in 2017.
Single-Cell, 42-plexed Protein Analysis Achieved with a New Microchip Technology
A novel microdevice capable of detecting 42 unique immune effector proteins has been developed.
Paramedics May be First Line of Treatment for Stroke
NIH study demonstrates feasibility of getting drugs to stroke patients faster.
Cancer Treatment with KU Origins Enters Second Clinical Trial
Cleave Biosciences has begun a Phase 1 clinical trial to evaluate CB-5083.
Ebola Vaccine Trial Opens in Liberia
Study led by Liberia-NIH partnership will test two experimental vaccines.
NIH Launches Tool to Advance Down Syndrome Research
Web portal will help approved professionals to plan clinical studies.
NIH Researchers Tackle Thorny Side of Gene Therapy
Pre-clinical studies in mice reveal ways to reduce cancer risk with modified treatment.
Early Blood Glucose Control Lengthens Life in People with Type 1 Diabetes
Reductions in diabetes complications resulting from tight glucose control translate into longer lifespans.
Oxford Vaccine Group Begins First Trial of New Ebola Vaccine
Oxford University doctors and scientists are starting the first safety trial of an experimental preventative Ebola vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).
GRP78 Protein Possible Universal Therapeutic Target
Drug combination including Viagra is effective tool in targeting the protein.
Scroll Up
Scroll Down
Return
RNA-Seq for High Throughput Clinical Studies
Wenzhong Xiao, Assistant Professor of Bioinformatics, Massachusetts General Hospital, speaking at Next-Gen Sequencing Congress 2011.
Date Posted: Thursday, December 15, 2011
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Phase 1 ALS Trial is First to Test Antisense Treatment of Neurodegenerative Disease
No serious adverse effects seem from central-nervous-system infusion of drug that blocks mutated protein.
Tuesday, April 09, 2013
 
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters